儿童液体难治性脓毒性休克不同血管活性药物策略的结局:系统评价与Meta分析
该系统评价与Meta分析检索至2023年12月,纳入13项报告儿童液体难治性脓毒性休克血管活性药特异性结局的随机对照试验和观察性队列研究,共997例患儿。12项研究共748例接受单一血管活性药,其中多巴胺361例、肾上腺素271例、去甲肾上腺素116例;单药总合并死亡率为12%(95%CI 6%-21%),多巴胺11%(95%CI 3%-36%)、肾上腺素17%(95%CI 6%-37%)、去甲肾上腺素7%(95%CI 1%-48%)。4项研究比较多巴胺(176例)与肾上腺素(142例),多巴胺死亡率有升高趋势(PR 1.38,95%CI 0.81-2.38),机械通气需求显著更高(PR 1.12,95%CI 1.02-1.22)。作者认为肾上腺素组机械通气需求更少、死亡率有降低趋势,需进一步研究明确一线血管活性药。
要点
- 儿童液体难治性脓毒性休克接受单一血管活性药者,去甲肾上腺素合并死亡率7%(95%CI 1%-48%),为三种药物中最低。
- 多巴胺单药合并死亡率11%(95%CI 3%-36%),肾上腺素单药合并死亡率17%(95%CI 6%-37%),单药总合并死亡率12%(95%CI 6%-21%)。
- 多巴胺(176例)与肾上腺素(142例)比较:多巴胺死亡率有升高趋势(PR 1.38,95%CI 0.81-2.38),未达统计学显著。
- 多巴胺较肾上腺素机械通气需求显著更高(PR 1.12,95%CI 1.02-1.22)。
- 作者认为需进一步研究以明确该人群的一线血管活性药。
适用人群与场景
- 儿童液体难治性脓毒性休克(FRSS)患者,纳入报告多巴胺、肾上腺素或去甲肾上腺素作为一线血管活性药特异性结局的随机对照试验和观察性队列研究。
处置流程与药物剂量
- 一线血管活性药包括多巴胺、肾上腺素或去甲肾上腺素,均为单药使用;12项研究748例中多巴胺361例、肾上腺素271例、去甲肾上腺素116例。
研究设计与关键结果
- 系统评价与Meta分析,检索MEDLINE、Embase、Scopus、CINAHL、Web of Science、Cochrane Library、ClinicalTrials.gov和ISRCTN注册库至2023年12月,共纳入13项研究、997例患儿。
- 12项研究748例接受单一血管活性药:多巴胺361例、肾上腺素271例、去甲肾上腺素116例。
- 单药总合并死亡率为12%(95%CI 6%-21%);多巴胺11%(95%CI 3%-36%)、肾上腺素17%(95%CI 6%-37%)、去甲肾上腺素7%(95%CI 1%-48%)。
- 4项研究比较多巴胺(176例)与肾上腺素(142例):多巴胺死亡率有升高趋势(PR 1.38,95%CI 0.81-2.38),未达统计学显著。
- 多巴胺较肾上腺素机械通气需求显著更高(PR 1.12,95%CI 1.02-1.22)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入随机对照试验和观察性队列研究;采用随机效应模型,同一研究内两药比较时计算患病率比(PR)。
- 局限:作者指出需进一步研究以更好界定该人群的一线血管活性药。
对床旁实践的改变
- 作者认为,在儿童液体难治性脓毒性休克接受单一血管活性药者中,去甲肾上腺素与最低死亡率相关;比较多巴胺与肾上腺素时,肾上腺素组机械通气需求更少、死亡率有降低趋势。
- 作者认为需进一步研究以明确该人群的一线血管活性药。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Hemodynamic support using vasoactive agents is a mainstay in the management of patients with pediatric fluid-refractory septic shock (FRSS). However, evidence supporting the appropriate choice of vasoactive agent is limited. This study aimed to perform a systematic review and meta-analysis on the effect of different first-line vasoactive strategies on mortality in pediatric FRSS. Methods: MEDLINE, Embase, Scopus, CINAHL, Web of Science, the Cochrane Library, ClinicalTrials.gov , and the ISRCTN registry were searched up until December 2023. Randomized controlled trials and observational cohort studies reporting vasoactive agent-specific outcomes of children with FRSS were included. Mortality was assessed as primary outcome in studies on patients receiving dopamine, epinephrine, or norepinephrine as first-line. Random-effects meta-analyses were conducted. Prevalence ratio (PR) estimates were calculated between two drugs when was available in the same study. Findings: Of the 26,284 identified articles, 13 were included, for a total of 997 children. Twelve studies included 748 patients receiving a single vasoactive agent. Of these, 361 received dopamine, 271 epinephrine, and 116 norepinephrine. Overall pooled mortality for patients receiving a single vasoactive was 12% (95% CI 6%-21%) of which 11% (95% CI 3%-36%) for patients receiving dopamine, 17% (95% CI 6%-37%) for epinephrine, and 7% (95% CI 1%-48%) for norepinephrine. Four first-line dopamine (176 patients) and first-line epinephrine (142 patients): dopamine showed a tendency toward higher mortality (PR 1.38, 95% CI 0.81-2.38) and a significant higher need for mechanical ventilation (PR 1.12, 95% CI 1.02-1.22). Interpretation: Among children with FRSS receiving a single vasoactive agent, norepinephrine was associated with the lowest mortality rate. Comparing dopamine and epinephrine, patients receiving epinephrine needed less mechanical ventilation and showed a trend for lower mortality rate. Further research is needed to better delineate the first-line vasoactive agent in this population.
参考来源
- Marchetto L, Zanetto L, Comoretto RI, et al. OUTCOMES OF PEDIATRIC FLUID-REFRACTORY SEPTIC SHOCK ACCORDING TO DIFFERENT VASOACTIVE STRATEGIES: A SYSTEMATIC REVIEW AND META-ANALYSIS. Shock. 2024. PMID: 39158574. doi:10.1097/SHK.0000000000002427
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。